Clinical trials: Patients With Type 2 Diabetes
Type2 Diabetes Mellitus
A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
The objectives of the study is to evaluate the efficacy, safety, and dose of DS-8500a compared with placebo in patients with type 2 diabetes mellitus.
- Trial name
- NCT02628392
- Testing
- DS-8500a, Sitagliptin
- Where
- Japan
- Volunteers
- 368 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
Multiple Electrode Aggregometry & Clopidogrel Resistance
Antiplatelet therapy with aspirin-clopidogrel reduces the risk of cardiovascular episodes after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD), Myocardial Infraction
- Trial name
- NCT01991093
- Where
- 3 sites in Greece
- Volunteers
- 280 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes.
- Trial name
- AWARD-1 (NCT01064687)
- Testing
- LY2189265, Exenatide, Metformin
- Where
- 89 sites in United States, Argentina and 2 more
- Volunteers
- 978 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to investigate the effects of blocking IL-1 signaling with AMG 108 in type 2 diabetes mellitus patients on glycemic control, as measured by change in HbA1c from baseline to end of treatment (EOT).
- Trial name
- NCT00661921
- Testing
- AMG 108
- Sponsor
- Amgen
Diabetes Mellitus, Type 2
A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine
This study will examine the influence of the basal insulins detemir and glargine on risk of cardiovascular death and death from all causes in patients treated by their general practitioner in United Kingdom (UK).
- Trial name
- NCT03960814
- Testing
- Insulin detemir
- Where
- Denmark
- Volunteers
- 12,847 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effect of canagliflozin on post-meal glucose blood levels in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01381887
- Testing
- Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hepatic Steatosis
Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes
The purpose is to assess the Safety, Tolerability, and Pharmacodynamics effect of IONIS DGAT2Rx in up to 45 Adult Patients with Type 2 Diabetes.
- Trial name
- NCT03334214
- Testing
- IONIS DGAT2Rx
- Where
- 22 sites in Canada, Hungary and 2 more
- Volunteers
- 44 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease
This study is conducted in Asia. The aim of this observational study is to investigate the clinical safety profile and effectiveness while using SC NovoRapid™ (insulin aspart) in patients with coexisting diabetes and kidney…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Chronic Kidney Disease
- Trial name
- NCT00849316
- Testing
- insulin aspart
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- AMPLITUDE-L (NCT03713684)
- Testing
- Efpeglenatide SAR439977, Background therapy
- Where
- 47 sites in United States, China and 1 more
- Volunteers
- 370 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
This is the first phase 3 randomized, double-blind, placebo/active-controlled clinical study to evaluate the efficacy and long-term safety of SAL067 in treatment-naive T2DM patients uncontrolled with diet and exercise…
- Trial name
- NCT05782192
- Testing
- SAL067, Alogliptin
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Diabetes Mellitus, Type 2
A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes
The main purpose of this study is to determine the safety of LY2409021 in healthy participants and participants with diabetes. The study drug is given as single oral doses.
- Trial name
- NCT01606371
- Testing
- LY2409021
- Where
- Singapore
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)
This is a prospective 24-week, randomized, parallel-group, multi-center, active-controlled (pioglitazone 45 mg) open-label study designed to assess the effects of tesaglitazar 2 mg per day on components of renal excretion of…
- Trial name
- NCT00229684
- Testing
- Tesaglitazar, pioglitazone
- Where
- 21 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.
- Trial name
- NCT03538743
- Testing
- PF-06882961
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Pfizer
Type 2 Diabetes
A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy
The purpose of this study is to evaluate the safety and efficacy of a range of doses of SK-0403 in subjects with type 2 diabetes that are not adequately controlled on metformin alone.
- Trial name
- NCT01169090
- Testing
- SK-0403, Sitagliptin
- Where
- 40 sites in United States
- Volunteers
- 620 people
- Sponsor
- Kowa Research Institute, Inc.
Type 2 Diabetes Mellitus
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Primary Objective: To evaluate the efficacy of fixed dose combination of glimepiride and metformin (AMARYL M 1/250mg) in comparison with glimepiride (AMARYL) alone in terms of glycemic control as reflected by HbA1c during a…
- Trial name
- NCT01457911
- Testing
- Glimepiride and Metformin hydrochloride combination (HOE490), Glimepiride (HOE490)
- Where
- 22 sites in China
- Volunteers
- 244 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients
This is a phase III, multicenter, randomized, double-blind, placebo-controlled study planning to include approximately 387 T2DM patients who have received at least 8 weeks of treatment with diet control and exercise； have not…
- Trial name
- NCT02477865
- Testing
- PEX168(100µg), PEX168(200µg)
- Volunteers
- 406 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type 2 Diabetes
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose…
- Trial name
- NCT07546929
- Testing
- HP-211
- Where
- 25 sites in United States
- Volunteers
- 300 people
- Sponsor
- Housey Healthcare ULC
Diabetes Mellitus, Type 2
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
This is an 80-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not…
- Trial name
- NCT00138619
- Testing
- vildagliptin
- Where
- 2 sites in United States, Germany
- Volunteers
- 478 people
- Sponsor
- Novartis
Type 2 Diabetes
Dapagliflozin DPPIV Inhibitor add-on Study
This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin).
- Trial name
- NCT00984867
- Testing
- Dapagliflozin
- Where
- 88 sites in United States, Argentina and 4 more
- Volunteers
- 833 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment in monotherapy in patients with…
- Trial name
- NCT01214239
- Testing
- Linagliptin
- Where
- 19 sites in China, Malaysia and 1 more
- Volunteers
- 300 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.